VERV Insider Trading Activity and SEC Form 4 Filings
VERV insider trading summary
No open-market insider purchases or sales of Verve Therapeutics, Inc. (VERV) have been reported on SEC Form 4 in the past 12 months.
Latest VERV insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Apr 2, 2025 | Troy Lister | Chief Scientific Officer | Sell | $9K (2,189 @ $4.15) |
| Apr 2, 2025 | Andrew D. Ashe | See Remarks | Sell | $11K (2,681 @ $4.15) |
| Apr 2, 2025 | Allison Dorval | Chief Financial Officer | Sell | $14K (3,350 @ $4.15) |
| Apr 2, 2025 | Joan Nickerson | Chief Administrative Officer | Sell | $12K (2,777 @ $4.15) |
| Apr 2, 2025 | Sekar Kathiresan | Chief Executive Officer | Sell | $41K (9,822 @ $4.15) |
| Apr 2, 2025 | Jason Politi | Chief Technical Ops. Off. | Sell | $13K (3,235 @ $4.15) |
| Dec 2, 2024 | Allison Dorval | Chief Financial Officer | Sell | $3K (555 @ $5.64) |
| May 14, 2024 | Andrew D. Ashe | See Remarks | Buy | $476K (76,000 @ $6.26) |
| Apr 2, 2024 | Joan Nickerson | Chief Administrative Officer | Sell | $12K (1,514 @ $8.24) |
| Dec 1, 2023 | Krishna Yeshwant | Insider | Buy | $18.0M (1,800,000 @ $10.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.